David Fiellin, MD
Associate Professor of Medicine and Investigative Medicine Section of General Internal Medicine

Mentee:

Robert (Douglas) Bruce

Dr. David Fiellin has focused his scholarly work on the interface between primary care and substance abuse. He conducts research on the transfer of treatment strategies, including opioid agonist maintenance with methadone and buprenorphine, from specialized settings to office-based, primary care and HIV specialty settings. He is coprincipal investigator on the Veteran’s Aging Cohort Study funded by the National Institute on Alcohol Abuse and Alcoholism, and co-investigator on the Health Resources Services Administration’s Buprenorphine in HIV Primary Care National Evaluation Center. Dr. Fiellin serves as the co chair of the Society of General Internal Medicine’s Substance Abuse Task Force and has served on the White House Office of National Drug Control Policy (ONDCP), Drug Control Research, Data, and Evaluation Advisory Committee. He currently serves on the World Health Organization and United Nations Office on Drugs and Crime Technical Guideline Development Group for psychosocially assisted pharmacologic treatment of opioid dependence.